Sareum Holdings Restarts SDC 1,801 Toxicology Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy SAR?
Source: Yahoo Finance
- Toxicology Study Restart: Sareum Holdings PLC has restarted the phase two toxicology study for SDC 1,801 with a new CRO, demonstrating the company's strong commitment to advancing its research pipeline.
- Clinical Trial Preparedness: The company has completed the manufacture of a GMP batch of SDC 1,801, ready for clinical trials, indicating thorough preparedness for the next phase of drug development.
- Partnership Expansion: Sareum is actively seeking partnerships for SRA 737, supported by extended IP and an active IND in the US, enhancing its attractiveness to potential partners in the pharmaceutical industry.
- Innovation Progress: The collaboration with receptor.AI for CNS diseases is progressing well, with a second batch of compounds in synthesis, showcasing the company's ongoing innovation and expansion into new therapeutic areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SAR
Wall Street analysts forecast SAR stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 20.920
Low
23.00
Averages
24.00
High
25.00
Current: 20.920
Low
23.00
Averages
24.00
High
25.00
About SAR
Saratoga Investment Corp. is a specialty finance company that provides customized financing solutions to United States middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its investment’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. The Company’s portfolio is comprised primarily of investments in leveraged loans issued by middle-market companies. It also invests in mezzanine debt and makes equity investments in middle-market companies. The Company’s investment activities are externally managed and advised by Saratoga Investment Advisors, LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Saratoga Investment Declares $0.25 Monthly Dividend
- Stable Monthly Dividend: Saratoga Investment has declared a monthly dividend of $0.25 per share, maintaining the previous level, which reflects the company's stability and commitment to returning value to shareholders in the current economic climate.
- Attractive Yield for Investors: The forward yield of 13.7% not only provides investors with substantial cash flow but also has the potential to attract more investors seeking high-yield opportunities in the market.
- Shareholder Record and Ex-Dividend Dates: The dividend will be payable on April 23, with a record date of April 7 and an ex-dividend date also on April 7, followed by additional payments on May 21 and June 23, ensuring timely returns for shareholders.
- Debt Financing Initiative: Saratoga Investment is also planning to issue $100 million in 7.50% unsecured notes due in 2031, which is expected to provide additional funding support and enhance the company's financial flexibility moving forward.
See More
Sareum Holdings Restarts SDC 1,801 Toxicology Study
- Toxicology Study Restart: Sareum Holdings PLC has restarted the phase two toxicology study for SDC 1,801 with a new CRO, demonstrating the company's strong commitment to advancing its research pipeline.
- Clinical Trial Preparedness: The company has completed the manufacture of a GMP batch of SDC 1,801, ready for clinical trials, indicating thorough preparedness for the next phase of drug development.
- Partnership Expansion: Sareum is actively seeking partnerships for SRA 737, supported by extended IP and an active IND in the US, enhancing its attractiveness to potential partners in the pharmaceutical industry.
- Innovation Progress: The collaboration with receptor.AI for CNS diseases is progressing well, with a second batch of compounds in synthesis, showcasing the company's ongoing innovation and expansion into new therapeutic areas.
See More
Updated Quant Ratings for Small-Cap Financial Stocks Post Earnings Season
- Top Rated Companies: Following the latest earnings season, both Saratoga Investment and AGF Management achieved a quant rating of 4.87, indicating strong fundamentals that are likely to attract more investor interest and potentially drive stock prices higher.
- Low Rated Companies: Coincheck Group N.V. received a quant rating of only 1.04, reflecting weak fundamentals that may lead to declining investor confidence and adversely affect its market performance.
- Market Trends: As the earnings season concludes, investors are shifting their focus to changes in quant ratings, which provide insights into company performance across valuation, growth, and profitability, potentially influencing future investment decisions.
- Industry Developments: Root plans to expand to all contiguous states by 2027, despite its current quant rating of 1.28, indicating that it faces volatility challenges in the rapidly growing auto insurtech sector.
See More
Morgan Stanley Cautions About Increasing Risks in Software Lending
S&P Software Index Decline: The S&P Software Index has experienced a significant decline of 22% this year due to the impact of AI.
Software Loan Price Stability: Despite the drop in the software index, the price of software loans has only decreased by approximately 3%.
See More
Saratoga Investment Prices $100M Unsecured Notes Offering
- Bond Offering Size: Saratoga Investment has successfully priced a $100 million offering of 7.50% unsecured notes due February 6, 2031, demonstrating the company's ability to raise capital and proactively manage future funding needs.
- Interest Payment Structure: The notes will accrue interest at an annual rate of 7.50%, with payments starting on May 31, 2026, and occurring quarterly on February 28, May 31, August 31, and November 30, ensuring stable returns for investors.
- Underwriter Purchase Option: The company granted underwriters an option to purchase an additional $15 million of notes, a strategy that not only provides flexible financing options but also allows for potential expansion of the offering in response to strong market demand.
- Listing Plans: The notes are expected to be listed on the NYSE under the symbol “SAV” within 30 days of issuance, which will enhance the company's market visibility and provide liquidity for investors.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference Shift: Amid market turbulence and uncertainty, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Rating Overview: Benzinga provides the latest analyst ratings on high-yield stocks, allowing investors to review the latest analyses of their favorite stocks by visiting the Analyst Stock Ratings page, thereby enhancing transparency in investment decisions.
- High-Yield Stock Recommendations: In the financial sector, PennyMac Mortgage Investment Trust (NYSE:PMT), Blue Owl Capital Corp (NYSE:OBDC), and Saratoga Investment Corp (NYSE:SAR) are highlighted as three high-yield stocks, reflecting market confidence in these companies.
- Analyst Accuracy: Benzinga's database enables traders to sort ratings by analyst accuracy, which not only improves investors' understanding of market dynamics but may also influence their investment strategies and choices.
See More
Saratoga Investment Declares $0.25 Monthly Dividend
- Stable Monthly Dividend: Saratoga Investment has declared a monthly dividend of $0.25 per share, maintaining the previous level, which reflects the company's stability and commitment to returning value to shareholders in the current economic climate.
- Attractive Yield for Investors: The forward yield of 13.7% not only provides investors with substantial cash flow but also has the potential to attract more investors seeking high-yield opportunities in the market.
- Shareholder Record and Ex-Dividend Dates: The dividend will be payable on April 23, with a record date of April 7 and an ex-dividend date also on April 7, followed by additional payments on May 21 and June 23, ensuring timely returns for shareholders.
- Debt Financing Initiative: Saratoga Investment is also planning to issue $100 million in 7.50% unsecured notes due in 2031, which is expected to provide additional funding support and enhance the company's financial flexibility moving forward.
See More
Sareum Holdings Restarts SDC 1,801 Toxicology Study
- Toxicology Study Restart: Sareum Holdings PLC has restarted the phase two toxicology study for SDC 1,801 with a new CRO, demonstrating the company's strong commitment to advancing its research pipeline.
- Clinical Trial Preparedness: The company has completed the manufacture of a GMP batch of SDC 1,801, ready for clinical trials, indicating thorough preparedness for the next phase of drug development.
- Partnership Expansion: Sareum is actively seeking partnerships for SRA 737, supported by extended IP and an active IND in the US, enhancing its attractiveness to potential partners in the pharmaceutical industry.
- Innovation Progress: The collaboration with receptor.AI for CNS diseases is progressing well, with a second batch of compounds in synthesis, showcasing the company's ongoing innovation and expansion into new therapeutic areas.
See More
Updated Quant Ratings for Small-Cap Financial Stocks Post Earnings Season
- Top Rated Companies: Following the latest earnings season, both Saratoga Investment and AGF Management achieved a quant rating of 4.87, indicating strong fundamentals that are likely to attract more investor interest and potentially drive stock prices higher.
- Low Rated Companies: Coincheck Group N.V. received a quant rating of only 1.04, reflecting weak fundamentals that may lead to declining investor confidence and adversely affect its market performance.
- Market Trends: As the earnings season concludes, investors are shifting their focus to changes in quant ratings, which provide insights into company performance across valuation, growth, and profitability, potentially influencing future investment decisions.
- Industry Developments: Root plans to expand to all contiguous states by 2027, despite its current quant rating of 1.28, indicating that it faces volatility challenges in the rapidly growing auto insurtech sector.
See More
Morgan Stanley Cautions About Increasing Risks in Software Lending
S&P Software Index Decline: The S&P Software Index has experienced a significant decline of 22% this year due to the impact of AI.
Software Loan Price Stability: Despite the drop in the software index, the price of software loans has only decreased by approximately 3%.
See More
Saratoga Investment Prices $100M Unsecured Notes Offering
- Bond Offering Size: Saratoga Investment has successfully priced a $100 million offering of 7.50% unsecured notes due February 6, 2031, demonstrating the company's ability to raise capital and proactively manage future funding needs.
- Interest Payment Structure: The notes will accrue interest at an annual rate of 7.50%, with payments starting on May 31, 2026, and occurring quarterly on February 28, May 31, August 31, and November 30, ensuring stable returns for investors.
- Underwriter Purchase Option: The company granted underwriters an option to purchase an additional $15 million of notes, a strategy that not only provides flexible financing options but also allows for potential expansion of the offering in response to strong market demand.
- Listing Plans: The notes are expected to be listed on the NYSE under the symbol “SAV” within 30 days of issuance, which will enhance the company's market visibility and provide liquidity for investors.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference Shift: Amid market turbulence and uncertainty, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Rating Overview: Benzinga provides the latest analyst ratings on high-yield stocks, allowing investors to review the latest analyses of their favorite stocks by visiting the Analyst Stock Ratings page, thereby enhancing transparency in investment decisions.
- High-Yield Stock Recommendations: In the financial sector, PennyMac Mortgage Investment Trust (NYSE:PMT), Blue Owl Capital Corp (NYSE:OBDC), and Saratoga Investment Corp (NYSE:SAR) are highlighted as three high-yield stocks, reflecting market confidence in these companies.
- Analyst Accuracy: Benzinga's database enables traders to sort ratings by analyst accuracy, which not only improves investors' understanding of market dynamics but may also influence their investment strategies and choices.
See More
